Amphastar P Total Liabilities
Amphastar P total liabilities. Based on the latest financial reports, Amphastar P (AMPH) has total liabilities worth $975.61 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Amphastar P (AMPH) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Amphastar P (2012–2025)
Total liabilities of Amphastar P from 2012 to 2025. This chart illustrates how Amphastar P's total liabilities have evolved over time, based on quarterly financial data. Explore AMPH strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Amphastar P Competitors by Total Liabilities
The table below lists competitors of Amphastar P ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EMTEK (Shenzhen) Co. Ltd.
SHE:300938
|
China | CN¥296.43 Million |
|
Shandong Oriental Ocean Sci-Tech Co Ltd
SHE:002086
|
China | CN¥311.73 Million |
|
Beijing Sanyuan Foods Co Ltd
SHG:600429
|
China | CN¥3.94 Billion |
|
Service Stream Ltd
AU:SSM
|
Australia | AU$533.37 Million |
|
Evergreen International Storage & Transport Corp
TW:2607
|
Taiwan | NT$12.63 Billion |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
USA | $8.84 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$4.44 Billion |
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
China | CN¥451.55 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Amphastar P's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AMPH total asset value.
Liquidity & Leverage Metrics
Amphastar P Total Liabilities Ratios Explained
Amphastar P total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amphastar P's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amphastar P (2012–2025)
The table below shows the annual total liabilities of Amphastar P from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $840.49 Million | -0.55% |
| 2024-12-31 | $845.17 Million | -3.24% |
| 2023-12-31 | $873.49 Million | +309.46% |
| 2022-12-31 | $213.33 Million | -5.61% |
| 2021-12-31 | $226.01 Million | +23.83% |
| 2020-12-31 | $182.51 Million | +14.47% |
| 2019-12-31 | $159.44 Million | +6.86% |
| 2018-12-31 | $149.20 Million | +27.16% |
| 2017-12-31 | $117.34 Million | +19.14% |
| 2016-12-31 | $98.48 Million | +4.08% |
| 2015-12-31 | $94.63 Million | -11.98% |
| 2014-12-31 | $107.51 Million | +23.29% |
| 2013-12-31 | $87.20 Million | +3.77% |
| 2012-12-31 | $84.04 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more